Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 19042984)

  • 1. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.
    Sturgeon CM; Duffy MJ; Hofmann BR; Lamerz R; Fritsche HA; Gaarenstroom K; Bonfrer J; Ecke TH; Grossman HB; Hayes P; Hoffmann RT; Lerner SP; Löhe F; Louhimo J; Sawczuk I; Taketa K; Diamandis EP;
    Clin Chem; 2010 Jun; 56(6):e1-48. PubMed ID: 20207771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers in clinical practice: a review focusing on common solid cancers.
    Duffy MJ
    Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
    Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
    Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
    Molina R; Barak V; van Dalen A; Duffy MJ; Einarsson R; Gion M; Goike H; Lamerz R; Nap M; Sölétormos G; Stieber P
    Tumour Biol; 2005; 26(6):281-93. PubMed ID: 16254457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
    Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of current bio- and molecular-markers in urological cancers].
    Shimazui T; Akaza H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
    Kramer BS; Gohagan J; Prorok PC; Smart C
    Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen (PSA) in breast and ovarian cancer.
    Kucera E; Kainz C; Tempfer C; Zeillinger R; Koelbl H; Sliutz G
    Anticancer Res; 1997; 17(6D):4735-7. PubMed ID: 9494598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
    Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
    Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tumor markers in patients with solid cancers: A critical review.
    Duffy MJ
    Eur J Intern Med; 2007 May; 18(3):175-84. PubMed ID: 17449388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical uses of tumor markers: a critical review.
    Duffy MJ
    Crit Rev Clin Lab Sci; 2001 Jun; 38(3):225-62. PubMed ID: 11451209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A personalized approach to cancer treatment: how biomarkers can help.
    Duffy MJ; Crown J
    Clin Chem; 2008 Nov; 54(11):1770-9. PubMed ID: 18801934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.